Views & Analysis Addressing MS’ two-tier healthcare system is about ‘social j... NICE has reversed its decision not to approve a new drug that offers hope to thousands o
News Roche’s MS drug Ocrevus earns blockbuster status a year afte... Roche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched.
News Roche’s MS drug Ocrevus nears European market Roche's new multiple sclerosis drug Ocrevus (ocrelizumab) gained FDA approval in March, and since then has achieved remarkable revenues of half a billion dollars in the year to date.<
News Brain infection would be bad news for Roche's MS drug Ocrevu... Suggestion is that PML case was caused by previous treatment.
Digital Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long... In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
